La historia detr\u00e1s de Invokana es muy similar a la de Januvia, Accutane, Byetta y otras drogas peligrosas<\/a>.<\/p>\n Millions of Americans suffer from Type 2 Diabetes. As the disease spread in the early 2000s, anti-diabetes drugs were at a premium. So, when Invokana (Canagliflozin) became available in 2013, many people hailed it as a miracle drug. Janssen Pharmaceuticals Johnson & Johnson division, aggressively marketed Invokana as a cutting-edge way to control diabetes and lose weight. Before long, the company had sold billions of dollars worth of Invokana worldwide.<\/p>\n But along the way, it appears that the company took dangerous shortcuts. In 2015, the Food and Drug Administration warned of possible serious complications, including diabetic ketoacidosis, bone fractures, and urinary tract infections. Later warnings included possible amputations and, in August 2018, Fournier\u2019s Gangrene. As a result, Invokana sales have tumbled almost 30 percent, and Janssen faces some 1,100 liability lawsuits.<\/p>\n These lawsuits seek compensation for actual losses, as well as punitive damages. The complex legal and factual issues involved demand highly-experienced representation. The professional team at Ley de N\u00e1poles<\/a> tiene las credenciales para manejar estos casos. Representamos a v\u00edctimas de drogas peligrosas a nivel nacional, por lo que contamos con los recursos que estos casos requieren. M\u00e1s importante a\u00fan, las grandes compa\u00f1\u00edas farmac\u00e9uticas no asustan a Paul J. Napoli y sus colegas. No retroceder\u00e1n. En cambio, luchar\u00e1n hasta el final para obtener la compensaci\u00f3n y la justicia que merece.<\/p>\n <\/p>\n Doctors were excited about Invokana because it inhibited subtype 2 sodium-glucose transport proteins. After several years of success in Europe, Canagliflozin was the first FDA-approved SGLT2 inhibitor.<\/p>\n SGLT2 proteins reabsorb about 90 percent of the body\u2019s glucose. Invokana blocks these transporters, enabling patients to pass over 100 grams of blood sugar per day through their urine. That means the excess blood sugar never enters the kidneys.<\/p>\n As a bonus, SGLT2 inhibitors, a class which also includes Xigduo XR, Qtern, Jardiance, Glyxambi, Synjardy, Invokamet, Invokamet XR, Farxiga, Synjardy XR, Steglatro, Segluromet and Steglujan, carry a very low risk of hypoglycemia (low blood sugar).<\/p>\n Issues with the drug approval system magnified problems with the drug itself. It costs an average of $2.5 billion just to bring a new drug to market. At the same time, Congress has slashed the length of drug patents. So, companies like Janssen must sell a lot of product in a short amount of time to show a healthy profit. They aggressively market these drugs and sometimes bury negative information.<\/p>\n\u00bfEs Invokana una droga peligrosa?<\/h2>\n